Da Wei Ma

Medicilon Puhui Pharmaceutical Technology (Shanghai) Co. Ltd, engages in the import and export of goods and technology. Its business scope includes technical services and consultation, technology development and transfer of pharmaceutical technology, biotechnology, and chemical technology; and sales of the first and second type of medical equipment. The company was founded on November 29, 2007 and is headquartered in Shanghai, China.

Bay Environmental Technology (Beijing) Corp. operates as an environmental protection service company. It specializes in volatile organic compounds treatment, vapor recovery system, PM2.5 treatment and low-nitrogen combustion, devotes us in providing complete environmental protection schemes to petrochemical industries and industrial enterprises. The company was founded by Wei Wei on July 12, 1994 and is headquartered in Beijing, China.

Yestar Aesthetic Medical Group Co., Ltd. engages in the provision of aesthetic medical services. It focuses on surgery and dermatology services. The company was founded by Guo Xing Chen and Guo Xion Chen on October 14, 2009 and is headquartered in Hangzhou, China.

China State Institute of Pharmaceutical Industry regulates pharmaceutical companies. The company is based in Shanghai, China. The Chinese company is a subsidiary ultimately controlled by the Government of China.

Part of Sinopharm Industrial Investment Co., Ltd., Sinopharm Holding Co., Ltd. functions as an investment holding Chinese company. The company is based in Haicang District, Hong Kong.

Shanghai Pudong Science & Technology Investment Co. Ltd. (PDSTI) is an independent Shanghai private equity and venture capital investment firm which was established in 1999, specializing in high-tech industries investments and M&A opportunities. Based in Shanghai, the firm focuses on the investment of integrated circuit, healthcare and other high-tech industries, and forms an experienced and professional team in M&A investment (domestic and cross-border), equity investments and other investment fields. PDSTI aims to commit itself to integrate the global high-tech industry resources, and enhance the corporate value, in order to portray itself as a global, dynamic and competitive world-class investment institution.

Part of Hepagene Therapeutics, Inc., Yatra Pharmaceutical Technology (Shanghai) Co., Ltd. is a Chinese company that engages in research and development of new drugs. The company is based in Shanghai, China. The company was founded in 2016 by Xiao Dong Xu.

Shenzhen Hua Xia Ren He Capital Management Co., Ltd. engages in asset management services. Its business also include equity investment, investment management, investment advice, enterprise management and consulting, and marketing planning. The company was founded on December 28, 2012 and is headquartered in Shenzhen, China.

Bellen Chemistry Co., Ltd. provides contract chemistry services. It offers chemical synthesis contract development and manufacturing organization (CDMO) services, chemical synthesis contract research organization (CRO) services, and drug molecular building blocks. The company was founded by Bo Liu, Li Xin Xing, Jian Hua Ren, Jian Xun Liu, and Yong Jun Jiang on January 28, 2010 and is headquartered in Beijing, China.

Suzhou Sinovent Pharmaceutical Technology Co. Ltd. is a private company that focuses on researching, developing, producing, and commercializing therapeutic drugs. The company is based in Suzhou, China.

China International Capital Corp. Ltd. (Broker) (CICC) is the brokerage division of China International Capital Corp. Ltd. which was established in 1995 as a strategic partnership between Chinese and international financial institutions and corporations. Headquartered in Beijing, CICC was the first joint venture investment bank in China. The firm's core business departments were investment banking, capital markets, sales & trading, research, fixed-income and asset management. CICC offers a range of brokerage services to international and domestic institutional and individual investors. In 2007 the firm set up a wholly-owned subsidiary specializing in private equity investments and focusing on buyout opportunities within China.